pembrolizumab,Carboplatin,Docetaxel,Pegfilgrastim
merck
['tnbc']
neopact shows 58% pcr in tnbc with anthracycline-sparing approach, including hr+low disease. #asco22 
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine